Key Takeaways
- Affinity Asset Advisors, Ikarian Capital acquired Kira Pharmaceuticals.
- Sector: Biotechnology & Life Sciences, Healthcare, Healthtech & Medtech.
- Geography: United States, China.
Analysis
Jasper Therapeutics has significantly expanded its clinical-stage immunology portfolio through the strategic acquisition of Kira Pharmaceuticals. This combination, finalized on July 16, 2026, creates a robust three-asset pipeline targeting a range of immune-mediated conditions, bolstered by a substantial concurrent financing round.
The newly formed entity is now equipped with enhanced operational capabilities spanning both the United States and China. This dual geographic presence is anticipated to accelerate the development of its promising therapeutic candidates. The acquisition itself was an all-stock transaction, integrating Kira's complement-focused programs into Jasper's existing development efforts.
Complementing the acquisition, Jasper Therapeutics secured approximately $132 million in gross proceeds through a private placement of non-voting convertible preferred stock. This crucial funding initiative was co-led by prominent life sciences investors Affinity Asset Advisors and Ikarian Capital, with additional participation from other key investors in the sector. This capital infusion provides a projected operational runway extending into the second half of 2028, enabling the advancement of multiple clinical programs.
The combined company's lead asset is now KP-104 (vensobafusp alfa), a bifunctional biologic poised for Phase 2/3 studies. This innovative therapy targets both the alternative and terminal pathways of the complement cascade, a critical system implicated in numerous inflammatory and autoimmune diseases. KP-104 is under investigation for rare kidney diseases and paroxysmal nocturnal hemoglobinuria (PNH), with interim data from a Phase 2 basket trial in rare renal indications expected in Q4 2026. Preparations are also underway for an end-of-Phase 2 meeting with the FDA regarding its PNH development.
Further strengthening the pipeline is briquilimab, an anti-KIT antibody in late-stage development for transplant and immunologic indications. Positive long-term data in severe combined immunodeficiency (SCID) is driving progress towards a potential pre-BLA meeting with regulatory authorities. The third key program, KP-701, represents a strategic entry into autoantibody-mediated diseases. This novel dual-acting antibody targets CD79b and CD32b, aiming to modulate B-cell activity. Clinical trial applications for KP-701 are anticipated in early 2027, marking its transition into human studies.
The strategic integration of Kira Pharmaceuticals and the successful completion of the significant financing round position Jasper Therapeutics to execute a multi-pronged development strategy. By advancing KP-104, progressing briquilimab towards regulatory milestones, and initiating Phase 1 studies for KP-701, the company is set to present multiple clinical and regulatory catalysts over the next two years. This diversified approach, supported by substantial capital, addresses a critical need for innovative therapies in immunology, a sector experiencing continuous innovation and investment.